23. Bryans, M., Kass, S., Seivwright, C., and Adams, R. L. (1992). Vector methylation 37.
inhibits transcription from the SV40 early promoter. FEBS Lett. 309: 97 – 102.
24. Brooks, A. R., Harkins, R. N., Wang, P., Qian, H. S., Liu, P., and Rubanyi, G. M. (2004).
Transcriptional silencing is associated with extensive methylation of the CMV promoter
following adenoviral gene delivery to muscle. J. Gene Med. 6: 395 – 404. 38.
25. Grimm, L., et al. (1998). Analysis of the human GDNF gene reveals an inducible
promoter, three exons, a triplet repeat within the 3V-UTR and alternative splice
products. Hum. Mol. Genet. 7: 1873 – 1886.
26. Moretto, G., et al. (1996). Expression and regulation of glial-cell-line-derived 39.
neurotrophic factor (GDNF) mRNA in human astrocytes in vitro. Cell Tissue Res.
286: 257 – 262.
27. Jing, S., et al. (1996). GDNF-induced activation of the ret protein tyrosine kinase is 40.
mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85: 1113 – 1124.
28. Wordinger, R. J., Lambert, W., Agarwal, R., Liu, X., and Clark, A. F. (2003). Cells of the 41.
human optic nerve head express glial cell line-derived neurotrophic factor (GDNF) and
the GDNF receptor complex. Mol. Vision 9: 249 – 256.
29. Kirik, D., Rosenblad, C., and Bjorklund, A. (1998). Characterization of behavioral 42.
and neurodegenerative changes following partial lesions of the nigrostriatal
dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. 43.
Neurol. 152: 259 – 277.
30. Marshall, J. F., and Ungerstedt, U. (1977). Supersensitivity to apomorphine following 44.
destruction of the ascending dopamine neurons: quantification using the rotational
model. Eur. J. Pharmacol. 41: 361 – 367. 45.
31. Hefti, F., Melamed, E., and Wurtman, R. J. (1980). Partial lesions of the
dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain
Res. 195: 123 – 137.
32. Hudson, J. L., et al. (1993). Correlation of apomorphine-and amphetamine-induced 46.
turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned
rats. Brain Res. 626: 167 – 174.
33. Lee, C. S., Sauer, H., and Bjorklund, A. (1996). Dopaminergic neuronal degeneration 47.
and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 72: 641 – 653.
34. Deumens, R., Blokland, A., and Prickaerts, J. (2002). Modeling ParkinsonTs disease in 48.
rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175:
303 – 317.
35. Checler, F., Barelli, H., Kitabgi, P., and Vincent, J. P. (1988). Neurotensin metabolism in 49.
various tissues of central and peripheral origins: ubiquitous involvement of a novel
neurotensin degrading metalloendopeptidase. Biochimie 70: 75 – 82.
36. Laurent, N., et al. (1999). Uptake by rat liver and intracellular fate of plasmid DNA 50.
complexed with poly-L-lysine or poly-D-lysine. FEBS Lett. 443: 61 – 65.
